NanoVibronix (NAOV) said Wednesday that it signed a non-binding term sheet for a license and supply agreement with Apogepha Arzneimittel for its UroShield urology therapy device.
The company said it and the German pharmaceutical company plan to enter into a definitive agreement under which Apogepha will distribute UroShield throughout Europe.
Financial terms were not disclosed.
The ultrasound-based product reduces catheter-associated urinary tract infections and decreases the pain and of urinary catheter use, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments